Angioedema Treatment Market, by Condition Type (Allergic Angioedema, Drug-induced Angioedema, Idiopathic Angioedema, and Hereditary Angioedema (HAE)), by Drug Type (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), by Route Of Administration (Injection and Oral), by Distribution Channel, and by Geography- Global Industry Insights, Trends, Outlook, And Opportunity Analysis, 2018-2026

Angioedema is the medical condition characterized by swelling of the lower layer of skin and tissue just under the skin or mucous membrane occurs. There are four main type of angioedema namely allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema (HAE). Angioedema is caused by various factors and in most of the cases exact cause is unknown. Major cause of angioedema are allergic reaction, adverse effect of any medication, genetic defects, and infections.

Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global angioedema treatment market

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/angioedema-treatment-market-1371

In 2017, U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients. In 2014, Pharming Group NV and Salix Pharmaceuticals, Ltd. received US Food and Drug Administration (FDA) approval for RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, indicated for the treatment of acute angioedema attacks in adult and adolescent patients with HAE. In 2016, CSL Behring received FDA approval for Berinert [C1 Esterase Inhibitor (Human)], indicated for the treatment of HAE attacks in pediatric patients. These multiple approvals of new drugs by regulatory bodies are expected to drive growth of global angioedema treatment market over the forecast period. Furthermore, initiatives taken by various organizations to support treatment of angioedema is also expected to support the growth of global angioedema treatment market. For instance in 2015, British Society for Allergy and Clinical Immunology (BSACI) provided a guideline for the management of chronic urticaria and angioedema. In 2013, the World Allergy Organization (WAO) also provided guideline for the Management of Hereditary Angioedema.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1371

Angioedema Treatment Market Taxonomy

The angioedema treatment market is segmented on the basis of condition type, drug type, route of administration, distribution channel, and geography

Europe is expected to be the second largest market for global angioedema treatment and it is also projected to witness a significant growth over the forecast period, owing to increasing number of new manufacturing plant in region. For instance in January 2018, Shire plc received U.S. Food and Drug Administration approval for the technology transfer of CINRYZE (C1 esterase inhibitor [human]) drug product manufacturing process to Vienna, Austria manufacturing site. CINRYZE is an injectable prescription medicine indicated for the treatment of HAE in teenagers and adults. North America is expected to hold the dominant position in global angioedema treatment market due to approval of new drugs indicated for the treatment of angioedema. For instance in 2014, Shire Canada Inc. received approval for its FIRAZYR (icatibant injection) in Canada. FIRAZYR is indicated for the treatment of acute attacks of HAE in adults with C1-esterase inhibitor deficiency.

Key players in angioedema treatment market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1-esterase-inhibitor (C1-INH) deficiency.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1371

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737